212Pb-DOTAM not checked

Roche · RO7205834-010 · 203Pb-DOTAM

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive 212Pb-DOTAM as a therapeutic radioligand per the schedule described in the protocol.”In the company’s words, NCT07416552 on ClinicalTrials.gov
Tested for
Metastatic Colorectal Cancer
Main trialPhase 1
“This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.”In the company’s words, NCT07416552 on ClinicalTrials.gov
Other names
RO7205834-010 · 203Pb-DOTAM · RO7205834-009

Other drugs for Metastatic Colorectal Cancer

All 392 drugs for Metastatic Colorectal Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 12 Feb 2034 A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow 212Pb-DOTAM

Following is part of Solo: you see every change to 212Pb-DOTAM the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in